Kamal Nahas

Kamal Nahas reports at the point where cutting-edge biology and technology meet the human body, turning dense experimental research into clear, tightly structured stories about how diseases are detected, treated and understood. He is a freelance science journalist and regular contributor to Live Science and other science publications, with work that spans experimental medicine, infectious disease, neuroscience, aging and the quirks of human physiology.

Experimental medicine and future therapies

Much of Nahas’ reporting follows new treatments from the lab bench toward the clinic, showing how experimental interventions could change care while staying precise about what has and hasn’t been tested. He has covered organ-on-a-chip research in which artificial tissue models are infected with gonorrhea and then used to test an antibiotic identified by artificial intelligence, explaining both how AI sifted millions of molecules and how the drug behaved in the model system.

He writes on regulatory shifts around gene therapies, including rules that allow certain tailor-made treatments for rare genetic disorders to bypass traditional clinical trials, and sets out who these therapies are meant to help and how safety monitoring is being structured. His coverage includes a new opioid candidate tested in rats that appears to relieve pain with a lower addiction risk than existing drugs, and he details the study design and what the early data do and do not show about safety. In a fetal surgery feature, he follows a high-stakes procedure in which surgeons operated in the womb at around 25 weeks’ gestation to resolve a life-threatening disorder, describing step by step how they exposed the fetus, intervened, and restored the pregnancy.

Across these pieces he consistently anchors breakthroughs in the specifics of animal studies, organ models and surgical techniques rather than broad hype, making his health coverage particularly strong on the mechanics of experimental medicine.

Mechanisms of immunity, aging and disease

Nahas repeatedly returns to stories that explain how the immune system, metabolism and aging processes work at a molecular level, using individual papers to illuminate bigger questions. He has written on the popular diabetes drug metformin, unpacking new evidence that it helps by pushing sugar into the intestines where gut bacteria convert it into chemicals that improve insulin responses, and clarifying how this resolves long-standing uncertainty about whether the drug acts mainly in the liver or gut.

His aging coverage includes work showing that human aging accelerates around ages 44 and 60, and he ties those inflection points to shifts in biological markers rather than vague notions of midlife.

He has reported on microplastics accumulating in the body and “clogging” immune cells, describing how particles interfere with cellular function and why this matters for long-term health. Another strand of his reporting looks at immune genes linked to larger brains and longer lifespans in mammals, including humans, connecting genetic pathways to both cognition and longevity.

He explains how fevers kill germs by walking through innate and adaptive immune responses, including how febrile temperatures boost immune activity and how dendritic cells present microbial fragments to other immune cells. Additional pieces examine epilepsy’s impact on sleep stages central to memory formation and the way this might prime the brain for future seizures, as well as how free-floating DNA with cancerous mutations can be detected in blood years before other signs of cancer.

This emphasis on mechanism gives his health stories a strong explanatory spine that goes beyond surface-level descriptions of risk and symptoms.

Diagnostic dilemmas and unusual clinical stories

Nahas’ work often spotlights puzzling or extreme clinical cases, using them to probe the limits of medical knowledge and decision-making.

In one Diagnostic Dilemma piece, he follows a man who sought advice from an AI chatbot about cutting out table salt, then developed paranoia and hallucinations severe enough to require hospitalization, tracing how the suggested substitution affected his physiology and mental state. Another Diagnostic Dilemma centers on a scientist who contracted plague from strains of bacteria that had been considered noninfectious, and he reconstructs the lab conditions and biosafety assumptions that allowed this exposure to occur. His feature on in-womb surgery not only details the sequence of the operation but also the balancing of risks for both fetus and pregnant patient, emphasizing how clinicians weigh immediate danger against long-term outcomes.

Across these stories he integrates narrative elements - timeline, individual choices, consequences - with careful reporting on pathophysiology and clinical protocols, making the cases feel grounded rather than sensational.

Origins, evolution and ‘quirky’ biology

Beyond clinical and translational work, Nahas regularly writes about the stranger corners of biology and the deep questions of how life works and began. At Live Science he has covered research on tiny “brains” grown in the lab that could, in principle, become conscious and feel pain, outlining the neural activity seen in these organoids and the ethical challenges of using them as models. He reports on RNA’s ability to fold into unexpectedly complex configurations, using those findings to raise questions about the role of RNA structures at the dawn of life on Earth. His health pieces also take on everyday but unusual phenomena, such as the chemicals that make babies smell “sweet” and teenagers smell “goat-like,” and he links these scent changes to developmental biology and skin chemistry rather than treating them as mere curiosities.

At other outlets he has written extensively on topics such as the origin of anesthesia, the emergence of cell nuclei, where viruses come from, the revival of Lamarckian ideas, the innate immune system’s tactics, and the role of archaea in the human microbiome, as well as on how artificial intelligence can be used to design proteins and support complex data analysis. These features show a consistent interest in the history and evolution of biological ideas and in the surprising ways microbes, molecules and technologies shape everyday life.

His cross-outlet portfolio includes work for major science magazines and journals, reinforcing a profile built around rigorous explanations of frontier biology rather than general-interest health advice.